Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.46 |
| ▸ | MIF | P14174 | 5/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ITGAM | P11215 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663617 | 0.92 | ITGB3 (0.44) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7666064 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7663989 | 0.91 | ITGB3 (0.51) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7666290 | 0.90 | ITGB3 (0.47) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7668496 | 0.89 | ITGB3 (0.48) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7661403 | 0.89 | MAPT (0.46) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7663448 | 0.88 | ITGB3 (0.47) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7534034 | 0.85 | ITGB3 (0.42) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7669754 | 0.85 | ITGB3 (0.62) | ITGB3ITGA2BMIFITGB2ITGAM | |
| SCHEMBL7673353 | 0.83 | ITGB3 (0.44) | ITGB3ITGA2BMIFITGB2ITGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | FGB, F2, F13B | ITGB3 268/4885ITGA2B 95/4885MIF 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.